Foundry Partners, LLC Ironwood Pharmaceuticals Inc Transaction History

Foundry Partners, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 05, 2024	BUY	$5.58 - $8.61 $75,910 - $117,130	13,604 Added 5.65%	254,177 $1.66 Million
Q1 2024 May 08, 2024	BUY	$8.32 - $15.45 $2 Million - $3.72 Million	240,573 New	240,573 $2.1 Million
Q2 2023 Jul 12, 2023	BUY	$10.1 - $11.6 $267,518 - $307,249	26,487 Added 5.82%	481,902 $5.13 Million
Q1 2023 May 03, 2023	BUY	$10.37 - $12.56 $255,516 - $309,478	24,640 Added 5.72%	455,415 $4.79 Million
Q4 2022 Jan 30, 2023	BUY	$9.9 - $12.43 $749,677 - $941,261	75,725 Added 21.33%	430,775 $5.34 Million
Q3 2022 Oct 21, 2022	BUY	$10.14 - $12.38 $383,535 - $468,261	37,824 Added 11.92%	355,050 $3.68 Million
Q2 2022 Jul 28, 2022	BUY	$11.05 - $12.72 $632,977 - $728,639	57,283 Added 22.04%	317,226 $3.66 Million
Q1 2022 Apr 14, 2022	SELL	$10.61 - $12.88 $6.02 Million - $7.31 Million	-567,790 Reduced 68.6%	259,943 $3.27 Million
Q4 2021 Jan 26, 2022	SELL	$10.86 - $13.95 $709,559 - $911,451	-65,337 Reduced 7.32%	827,733 $9.65 Million
Q3 2021 Oct 14, 2021	BUY	$11.92 - $13.92 $10.6 Million - $12.4 Million	893,070 New	893,070 $11.7 Million

238

162M

11.2M

9.1K

Ticker IRWD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 153,231,008
Market Cap $541M
Description
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZE...

Get notified when there are updates to the investment portfolio of Foundry Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Foundry Partners, LLC with notifications on news.